MADRIGAL PHARMACEUTICALS, INC. Net Income Loss

Quick Answer

MADRIGAL PHARMACEUTICALS, INC. reported Net Income Loss of -$288.28 million for the year ending 2025.

  • MADRIGAL PHARMACEUTICALS, INC. showed an increase of +38.1% in Net Income Loss from 2024 to 2025.
  • This data is from MADRIGAL PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 19, 2026.
  • XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 10 years of available data (2016 to 2025), MADRIGAL PHARMACEUTICALS, INC.'s Net Income Loss has declined by 992.5%.
  • Historical annual values: Fiscal year 2025: -$288.28 million | Fiscal year 2024: -$465.89 million | Fiscal year 2023: -$373.63 million | Fiscal year 2022: -$295.35 million | Fiscal year 2021: -$241.85 million | Fiscal year 2020: -$202.24 million | Fiscal year 2019: -$83.95 million | Fiscal year 2018: -$32.81 million | Fiscal year 2017: -$31.15 million | Fiscal year 2016: -$26.39 million.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: